BioSpace News Archive

DocGo™ leverages its technology, infrastructure and staff across the U.S. and the U.K. to provide on-site services that bridge the gap between physical and virtual care in a convenient, affordable and resource-optimized way.

Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33 rd Annual Roth Conference being held March 15-17, 2021.

New Drug Application (NDA) for once-nightly FT218 to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy accepted for filing by the FDA; assigned a Prescription Drug User Fee Act (PDUFA) target date of October 15, 2021 Completed key appointments for Commercial, Clinical and Medical Affairs functions to lead launch planning and readiness to capitalize on significant market opportunity

-- Fourth quarter 2020 net revenues of $57.3 million; net loss of $3.6 million and diluted loss per share of $0.30 -- -- Fourth quarter adjusted non-GAAP EBITDA of $17.2 million and adjusted non-GAAP diluted eps of $0.80 -- -- ANI defines strategy for sustainable future growth and strengthens capital structure --

BioVie Inc., a clinical-stage company developing innovative drug therapies for liver disease, announced the start of patient screening in the Company’s Phase 2 Trial of BIV201 for the treatment of refractory ascites.

–Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021– –Up to 8 clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET–

LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, has been invited to participate at the 33 rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021.

BD, a leading global medical technology company, announced an agreement with ImageMover, a software platform that automates and simplifies medical data collection and management, to offer a companion mobile app that enables more streamlined reporting of SARS-CoV-2 antigen testing results performed on the BD Veritor™ Plus System at everyday testing locations, such as schools and businesses.

Alphamab Oncology (stock code: 9966.HK) announced that U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) to initiate an open label, multi-center phase II pivotal clinical study (clinical trial No.: KN046-205) in the United States to evaluate the efficacy

The peer-reviewed article published in Cancer Discovery, a journal of the American Association for Cancer Research Anat Cohen-Dayag, Ph.D., President and CEO of Compugen: Our discovery of PVRIG as a distinct pathway in the DNAM axis has evolved into a deep and broad understanding of this potentially foundational axis in cancer immunotherapy [09-March-2021]